06 January 2025
06 January 2025
There are more than 300 GLP-1RAs in an active stage of development, from industry giants and potential market disrupters.
The approval marks the third indication for therapy in China for an IL-5 mediated condition.
Distinguishing the stages of fibrosis in MASH is a pressing need for diagnoses and clinical trials.
iPSCs are intended for use in treatments for various neurodegenerative diseases.
The hydrogels acts as a stable reservoir, delivering medication in a regulated manner and sparing healthy cells.
Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
